Tumor necrosis factor-α (TNF-α), interleukin-17 (IL-17), interleukin-6 (IL-6), interleukin-4 (IL-4) antibodies and other drugs have been proven useful in treating rheumatoid arthritis (RA), psoriasis, cytokine release syndrome (CRS), atopic dermatitis (AD) and other autoimmune diseases (15–18). Here, IL17A is linked to psoriasis.